Oncotarget

Research Papers:

Cuprous oxide nanoparticles inhibit the growth of cervical carcinoma by inducing autophagy

Leilei Xia, Ye Wang, Ya Chen, Jiuqiong Yan, Fan Hao, Xiaoling Su, Caihong Zhang and Mingjuan Xu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:61083-61092. https://doi.org/10.18632/oncotarget.17854

Metrics: PDF 1394 views  |   HTML 3071 views  |   ?  


Abstract

Leilei Xia1,*, Ye Wang2,*, Ya Chen3, Jiuqiong Yan1, Fan Hao1, Xiaoling Su1, Caihong Zhang1 and Mingjuan Xu1

1Department of Obstetrics and Gynaecology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China

2Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China

3Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Mingjuan Xu, email: [email protected]

Keywords: cuprous oxide nanoparticle, cervical cancer, nanomedicine, therapy, AKT/mTOR pathway

Abbreviations: DDP: Cisplatin.

Received: February 13, 2017    Accepted: April 12, 2017    Published: May 15, 2017

ABSTRACT

Cervical carcinoma is one of the main causes of women’s cancer, and substantial side effects from standard treatment including platinum-based chemotherapy limit the options for escalation. In this paper, using cervical cancer cell lines and tumor-bearing mice as models, we report that CONPs could inhibit the proliferation of cancer cells in vitro and in vivo. Especially CONPs could inhibit tumor growth as cisplatin without weight loss. CONPs could also induce autophagy through AKT/mTOR pathway, which demonstrates that CONPs has the potential clinical applications.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17854